Literature DB >> 11579309

The use of liver grafts from donors with bacterial meningitis.

S Satoi1, S R Bramhall, M Solomon, M Hastings, A D Mayer, J V de Goyet, J A Buckels, P McMaster, D F Mirza.   

Abstract

BACKGROUND: The shortage of suitable donors for transplantation is a worldwide problem. The use of cadaveric donors with bacterial meningitis may be associated with an increased risk of sepsis. We report the results of orthotopic liver transplantation (OLT) from 33 such donors between 1989 and 1999.
METHODS: The hospital records of recipients from cadaveric donors with meningitis (study group) were retrospectively reviewed and compared with matched recipients from cadaveric donors dying from causes other than meningitis (recipient-matched control group).
RESULTS: A total of 34 recipients underwent 21 whole, 10 reduced, and 3 split liver transplants from 33 cadaveric donor livers with bacterial meningitis. The donor meningitis pathogens were Neisseria meningitidis (n=14), Streptococcus pneumoniae (n=4), Haemophilus influenzae (n=1), Streptococcus species (n=2), and unknown (n=12). Twenty-seven patients had an elective OLT and seven patients had an emergency OLT. Adequate antimicrobial therapy before organ procurement and after transplant was administrated. The mean posttransplant follow-up was 37 months (range: 1 day-106 months). There was no difference in recipient and graft survival rates between the study and the recipient-matched groups. In the study group, there were no infectious complications caused by the meningeal pathogens. Overall patient survival rates were 79%, 76%, 72%, and 72% at 1, 6, 12, and 60 months, respectively. Graft survival was 77%, 70%, 65%, and 65% at 1, 6, 12, and 60 months, respectively. The survival rate in elective cases was significantly better than emergency cases (P<0.05).
CONCLUSION: Liver transplantation from donors with bacterial meningitis is a safe procedure provided both donors and recipients receive adequate antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579309     DOI: 10.1097/00007890-200109270-00022

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Non-heart beating organ donation: old procurement strategy--new ethical problems.

Authors:  M D D Bell
Journal:  J Med Ethics       Date:  2003-06       Impact factor: 2.903

2.  In defense of the reverence of all life: Heideggerean dissolution of the ethical challenges of organ donation after circulatory determination of death.

Authors:  D J Isch
Journal:  Med Health Care Philos       Date:  2007-05-02

Review 3.  Opportunistic infections--coming to the limits of immunosuppression?

Authors:  Jay A Fishman
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

4.  Evaluation of bacterial infections in organ transplantation.

Authors:  Sílvia Figueiredo Costa; Maristela Pinheiro Freire; Leonardo Borges B Silva; Edson Abdala; Lígia Pierrotti; Luis Sérgio Fonseca de Azevedo; Pedro Enrique Dorhiac-Llacer; Tania Mara Varejão Strabelli; Maria Aparecida Shikanai-Yasuda
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

5.  Neisseria meningitidis endotoxin and capsule transmission by transplantation.

Authors:  Nareg Roubinian; Beth D Kirkpatrick; Freyja Lynn; Jonathan Zenilman; Margaret Bash
Journal:  Emerg Infect Dis       Date:  2005-08       Impact factor: 6.883

Review 6.  Screening of donor and recipient prior to solid organ transplantation.

Authors: 
Journal:  Am J Transplant       Date:  2004-11       Impact factor: 8.086

7.  Successful renal transplantation from a deceased donor who died of bacterial meningitis.

Authors:  V B Kute; A V Vanikar; H V Patel; M R Gumber; P R Shah; P R Modi; H L Trivedi
Journal:  Indian J Nephrol       Date:  2014-09

Review 8.  Donor-derived infection--the challenge for transplant safety.

Authors:  Jay A Fishman; Paolo A Grossi
Journal:  Nat Rev Nephrol       Date:  2014-09-02       Impact factor: 28.314

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.